Buy Aurobindo Pharma Ltd For Target Rs.1,080 - Yes Securities
Our View
* Strong momentum in injectables business to support US business as acceleration unlikely in slow growing oral solids
* Steady margin uptick over next 2 years as better margin injectables business offset to an extent by lackluster oral solids profitability
* Net cash balance sheet offers comfort; as also gives firepower to plug gaps in US portfolio
* FY21 estimates change as gains from Natrol sale are crystalized; minor 2% cut to FY23 EPS on marginally lower US sales assumption
* BUY stays on unchanged 15x PE; sustained execution to drive stock upside
Highlights
* Adjusted for Natrol, US revs up 10% yoy vs reported 6% yoy. Cc growth at 2% yoy on reported basis. Injectables business remains on strong growth trajectory
* Europe cc growth less than 2% yoy as sales benefited from 12% yoy FX tailwind; company expects European margin to pick up pace from current low double digit run rate
* Margin stood at 21.5% with a gain of 100bps yoy. Gain could have been higher but for loss of export incentive and lack of 1mth of Natrol sales
* Auro took Rs4.3bn provisional write off relating to business and covid in some markets
Risk to our call
Any increased competition in injectables can lead to margin deterioration pretty quickly
To Read Complete Report & Disclaimer Click Here
Please refer disclaimer at https://yesinvest.in/privacy_policy_disclaimers
SEBI Registration number is INZ000185632
Above views are of the author and not of the website kindly read disclaimer
